• 
    

    
    

      99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看

      ?

      新型含1,3,4-噻二唑的硫色滿酮衍生物的合成及其抗真菌活性*

      2016-01-17 08:53:54梁國超鐘一凡韓曉燕宋亞麗河北大學(xué)a藥學(xué)院河北省藥品質(zhì)量控制重點(diǎn)實(shí)驗(yàn)室教育部藥物化學(xué)與分子診斷重點(diǎn)實(shí)驗(yàn)室河北保定071002
      合成化學(xué) 2015年12期
      關(guān)鍵詞:噻二唑乙酰胺酰胺

      梁國超,周 冠,鐘一凡,韓曉燕,宋亞麗(1.河北大學(xué)a.藥學(xué)院河北省藥品質(zhì)量控制重點(diǎn)實(shí)驗(yàn)室; b.教育部藥物化學(xué)與分子診斷重點(diǎn)實(shí)驗(yàn)室,河北保定 071002)

      ?

      新型含1,3,4-噻二唑的硫色滿酮衍生物的合成及其抗真菌活性*

      梁國超1a,1b,周冠1a,1b,鐘一凡1a,1b,韓曉燕1a,1b,宋亞麗1a,1b
      (1.河北大學(xué)a.藥學(xué)院河北省藥品質(zhì)量控制重點(diǎn)實(shí)驗(yàn)室; b.教育部藥物化學(xué)與分子診斷重點(diǎn)實(shí)驗(yàn)室,河北保定071002)

      摘要:以取代苯硫酚和順丁烯二酸酐為原料,經(jīng)邁克爾加成反應(yīng)制得2-羧基-硫色滿酮衍生物(2a~2d); 2a~2d分別與氨基硫脲反應(yīng)制得2-(5-氨基-1,3,4-噻二唑-2-基)硫色滿-4-酮衍生物(3a~3d); 3a~3d與酰氯經(jīng)?;磻?yīng)合成了14個(gè)新型的含1,3,4-噻二唑的硫色滿酮衍生物(5a~5n),其結(jié)構(gòu)經(jīng)1H NMR,13C NMR和HRESI-MS表征。采用微量稀釋法測(cè)定了5a~5n的抗真菌活性。結(jié)果表明:部分化合物對(duì)絮狀表皮癬菌和總狀毛霉菌有較好的抑制活性,優(yōu)于陽性對(duì)照藥氟康唑。

      關(guān)鍵詞:硫色滿酮; 1,3,4-噻二唑;合成;抗真菌活性

      課題;河北大學(xué)自然科學(xué)基金資助項(xiàng)目(2010-194)

      通信聯(lián)系人:宋亞麗,教授,E-mail:yalisong@ hbu.edu.cn

      1,3,4-噻二唑是許多天然產(chǎn)物和藥物中的重要結(jié)構(gòu)片段,具有抗菌和抗真菌[1]、抗炎[2]、抗腫瘤[3]和抗病毒[4]等生物活性。

      Scheme 1

      Matysiak J等[1]合成了一系列5-取代-2-(2,4-二羥基苯基)-1,3,4-噻二唑衍生物(Ⅰ),并對(duì)其進(jìn)行了抗念珠菌活性測(cè)定。結(jié)果顯示:當(dāng)噻二唑的2-位取代基為甲基和苯基時(shí),Ⅰ顯示出較高的抗真菌活性。Rebolledo C L等[5]合成了辣椒素類似物——1,3,4-噻二唑烷基酰胺衍生物(Ⅱ),并測(cè)定了其對(duì)HEK-293T細(xì)胞的TRPV1受體生物活性。結(jié)果表明:Ⅱ是瞬時(shí)受體TRPV1的潛在拮抗劑,可作為潛在的抗炎止痛藥物。Shen L H等[6]合成了一系列1,3,4-噻二唑類N-甲基秋水仙素酰胺衍生物(Ⅲ),并對(duì)Ⅲ的抗癌活性進(jìn)行了測(cè)定。結(jié)果顯示,多數(shù)目標(biāo)化合物具有較好的抗癌活性,對(duì)所篩選癌細(xì)胞的抑制性高于秋水仙素。

      硫色滿酮類化合物以多種形式存在于自然界的植物體中[7],具有抗炎、抗菌[8-9]及抗癌[10]等生物活性。目前,人們對(duì)此類化合物的合成和生物活性已做了大量研究,合成了多種硫色滿酮的衍生物。研究結(jié)果顯示:3-位Mannich堿取代[8-9],3-位次芐基取代[11],3-位烴基取代[12]及2-烷基取代[13]的硫色滿酮衍生物,大部分都有很好的抗癌抗真菌活性。

      根據(jù)藥物活性基團(tuán)的疊加原理,本文以取代苯硫酚(1a~1d)和順丁烯二酸酐為原料,經(jīng)邁克爾加成反應(yīng)制得2-羧基-硫色滿酮衍生物(2a~2d); 2a~2d分別與氨基硫脲反應(yīng)制得2-(5-氨基-1,3,4-噻二唑-2-基)硫色滿-4-酮衍生物(3a~3d); 3a~3d與酰氯(4a,4e,4g,4k和4m)經(jīng)?;磻?yīng)合成了14個(gè)新型的含1,3,4-噻二唑的硫色滿酮衍生物(5a~5n,Scheme 1),其結(jié)構(gòu)經(jīng)1H NMR,13C NMR和HR-ESI-MS表征。采用微量稀釋法對(duì)測(cè)定了5a~5n對(duì)5種真菌[新生隱球菌(C.n),白色念珠菌(C.a),絮狀表皮癬菌(E.f),總狀毛霉(M.r)和克柔念珠菌(C.k)]的抑制活性。

      1 實(shí)驗(yàn)部分

      1.1儀器與試劑

      SGWX-4型顯微熔點(diǎn)儀(溫度未校正); Bruker AVШ-600 MHz型核磁共振儀(DMSO-d6為溶劑,TMS為內(nèi)標(biāo)); Bruker Apex Ultra 7.0 T型傅里葉變換離子回旋質(zhì)譜儀。

      C.n,C.a,E.f,M.r和C.k,中國醫(yī)學(xué)科學(xué)院菌種保藏中心;其余所用試劑均為分析純。

      1.2合成

      (1)2a~2d的合成通法

      在圓底燒瓶中加入1a~1d 50 mmol,順丁烯二酸酐4.9 g(50 mmol)和甲苯15 mL,攪拌下于50℃滴加三乙胺1 mL的甲苯(5 mL)溶液,滴畢,于70℃反應(yīng)20 min。減壓蒸除溶劑,殘余物用二氯甲烷50 mL溶解。冰浴冷卻下,緩慢加入無水三氯化鋁10.0 g(75 mmol),反應(yīng)2 h(TLC檢測(cè))。加入二氯甲烷100 mL稀釋,依次加入冰塊和濃鹽酸20mL,析出沉淀。抽濾,濾餅用95%乙醇重結(jié)晶兩次得淡黃色粉末2a~2d,收率80%~87%。

      6-氯-2-羧基硫色滿-4-酮(2b):收率84%,m.p.134℃~136℃;1H NMR δ:7.91(d,J=2.4 Hz,1H,ArH),7.57(dd,J=8.4 Hz,2.4 Hz,1H,ArH),7.43(d,J=8.4 Hz,1H,ArH),5.21(t,J=4.8 Hz,1H,2-H),3.38(dd,J=16.8 Hz,4.8 Hz,1H,3-H),3.30(dd,J=16.8 Hz,4.8 Hz,1H,3-H);13C NMR δ:157.60,137.38,133.89,132.17,130.98,130.60,127.61,115.54,42.97,39.24; HR-ESI-MS m/z:Calcd for C10H8O3SCl{[M + H]+} 242.980 4,found 242.978 9。

      (2)3a~3d的合成通法

      在反應(yīng)瓶中加入氨基硫脲0.91 g(10 mmol),2a~2d 10 mmol和三氯氧磷15 mL,攪拌使其溶解;于80℃反應(yīng)10 min。冷卻至室溫,冰水浴冷卻下于30 min內(nèi)緩緩滴加水45 mL,滴畢,于80℃反應(yīng)3 h。反應(yīng)液冷卻至室溫,倒入冰水中,攪拌出現(xiàn)沉淀。冰水浴冷卻下用1 mol·L-1NaOH溶液調(diào)至pH 8~9,析出大量棕色沉淀;抽濾,濾餅用混合溶劑[V(DMF)∶V(H2O)=1∶2]重結(jié)晶得棕黃色粉末3a~3d,收率50%~65%。

      2-氨基-5-(6-氟-硫色滿-4-酮-2-基)-[1,3,4]噻二唑(3a):收率54%,m.p.160℃~161℃;1H NMR δ:7.70(dd,J=8.4 Hz,2.8 Hz,1H,ArH),7.44(dd,J=8.4 Hz,5.4 Hz,1H,ArH),7.43~7.40(m,1H,ArH),7.25(s,2H,NH2),5.19(t,J=4.8 Hz,1H,2-H),3.37(dd,J=16.8 Hz,4.8 Hz,1H,3-H),3.29(dd,J=16.8 Hz,4.8 Hz,1H,3-H);13C NMR δ:191.42,170.01,161.45,159.83,157.76,134.02,134.00,132.47,132.43,130.90,130.85,122.07,121.92,114.35,114.20,42.99,39.30; HR-ESI-MS m/z:Calcd for C11H9N3OS2F{[M + H]+} 282.009 3,found 282.007 5。

      (3)5a~5n的合成通法

      在圓底燒瓶中加入3a~3d 10 mmol,三乙胺1.01 g(10 mmol)和DMF 50 mL,攪拌使其溶解;于室溫緩慢滴加4 12 mmol的DMF(10 mL)溶液,滴畢,反應(yīng)0.5 h~1.0 h。加水20 mL,有沉淀析出。抽濾,濾餅用混合溶劑[V(乙醇)∶V(DMF)=1∶5]重結(jié)晶得淡棕色粉末5a~5n。

      N-5-(6-氟-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-乙酰胺(5a):收率90%,m.p.260℃~262 ℃;1H NMR δ:12.47(s,1H,NH),7.71(dd,J=9.5 Hz,2.8 Hz,1H,ArH),7.48~7.39(m,2H,ArH),5.40(t,J=5.4 Hz,1H,2-H),3.48(dd,J=17.4 Hz,5.4 Hz,1H,3-H),3.38(dd,J=17.4 Hz,5.4 Hz,1H,3-H),2.15(s,3H,COCH3);13C NMR δ:191.42,169.28,164.02,161.48,159.96,159.86,133.79,133.77,132.40,132.36,130.95,130.90,122.18,122.03,114.38,114.23,42.84,38.77,22.76.HR-ESI-MS m/z:Calcd for C13H11N3O2S2F{[M + H]+} 324.027 1,found 324.026 7。

      N-5-(6-氯-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-乙酰胺(5b):收率85%,m.p.250℃~252 ℃;1H NMR δ:12.49(s,1H,NH),7.92(d,J=2.4 Hz,1H,ArH),7.56(dd,J=8.4 Hz,2.4 Hz,1H,ArH),7.44(d,J=8.4 Hz,1H,ArH),5.42(t,J=4.8 Hz,1H,2-H),3.47(dd,J=17.4 Hz,4.8 Hz,1H,3-H),3.40(dd,J=17.4 Hz,4.8 Hz,1H,3-H),2.15(s,3H,COCH3);13C NMR δ:195.90,173.97,168.59,164.76,141.94,138.78,136.83,135.82,135.40,132.38,47.54,43.44,27.54; HR-ESI-MS m/z:Calcd for C13H11N3O2S2Cl{[M + H]+} 339.997 6,found 339.998 2。

      N-5-(6,8-二甲基-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-乙酰胺(5c):收率90%,m.p.284℃~285℃;1H NMR δ:12.47(s,1H,NH),7.69(s,1H,ArH),7.27(s,1H,ArH),5.36(t,J=4.8 Hz,1H,2-H),3.43(dd,J=16.8 Hz,4.8 Hz,1H,3-H),3.32(dd,J=16.8 Hz,4.8 Hz,1H,3-H),2.26(s,3H,ArCH3),2.22(s,3H,ArCH3),2.14(s,3H,COCH3);13C NMR δ:191.89,168.00,165.39,160.09,136.74,135.71,135.09,133.24,130.09,126.19,42.79,38.02,21.06,20.46,19.63; HR-ESI-MS m/z:Calcd for C15H16N3O2S2{[M +H]+}334.067 8,found 334.068 0。

      N-5-(6-甲基-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-乙酰胺(5d):收率85%,m.p.249℃~252℃;1H NMR δ:12.46(s,1H,NH),7.80(d,J=1.8 Hz,1H,ArH),7.33(dd,J=8.4 Hz,1.8 Hz,1H,ArH),7.26(d,J=8.4 Hz,1H,ArH),5.33(t,J=4.8 Hz,1H,2-H),3.45(dd,J=16.8 Hz,4.8 Hz,1H,3-H),3.35(dd,J=16.8 Hz,4.8 Hz,1H,3-H),2.29(s,3H,ArCH3),2.14(s,3H,COCH3);13C NMR δ:192.17,169.16,164.42,159.84,135.87,135.31,134.81,130.68,128.70,128.43,43.41,38.88,22.78,20.82; HR-ESI-MS m/z:Calcd for C14H14N3O2S2{[M +H]+}320.052 2,found 320.052 9。

      N-5-(6-氯-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-苯甲酰胺(5e):收率80%,m.p.362℃~365 ℃;1H NMR δ:12.98(s,1H,NH),8.07(d,J=7.2 Hz,2H,ArH),7.94(d,J=2.4 Hz,1H,ArH),7.69~7.43(m,5H,PhH),5.48(t,J=4.8 Hz,1H,2-H),3.52(dd,J=17.4 Hz,4.8 Hz,1H,3-H),3.43(dd,J=17.4 Hz,4.8 Hz,1H,3-H);13C NMR δ:191.20,166.45,164.33,160.98,137.23,134.03,133.50,132.10,131.13,130.66,129.72,129.09,128.87,127.66,42.84,38.78; HR-ESI-MS m/z:Calcd for C18H13N3O2S2Cl{[M + H]+}402.013 2,found 402.013 1。

      N-5-(6,8-二甲基-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-苯甲酰胺(5f):收率80%,m.p.343℃~345℃;1H NMR δ:12.98(s,1H,NH),8.07(dd,J=8.4 Hz,1.2 Hz,2H,ArH),7.95(d,J=8.4 Hz,1H,ArH),8.08~7.26(m,4H,ArH),5.42(dd,J=5.4 Hz,5.4 Hz,1H,2-H),3.48(dd,J=16.8 Hz,5.4 Hz,1H,3-H),3.36(dd,J=16.8 Hz,5.4 Hz,4H,3-H),2.26(s,3H,ArCH3),2.24(s,3H,ArCH3);13C NMR δ:192.48,167.77,164.85,162.77,136.38,135.78,134.77,134.50,133.47,133.31,130.95,129.72,129.08,129.01,128.86,126.59,43.10,38.24,20.71,19.88; HR-ESI-MS m/z:Calcd for C20H18N3O2S2{[M +H]+}396.083 5,found 396.083 9。

      N-5-(6-氟-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-2-氯-乙酰胺(5g):收率85%,m.p.225℃~227℃;1H NMR δ:12.87(s,1H,NH),7.71(dd,J=9.4 Hz,2.8 Hz,1H,ArH),7.48~7.39(m,2H,ArH),5.43(t,J=4.7 Hz,1H,2-H),4.41(s,2H,CH2Cl),3.49(dd,J=17.4 Hz,4.8 Hz,1H,3-H),3.40(dd,J=17.4 Hz,4.8 Hz,1H,3-H);13C NMR δ:191.30,166.00,164.71,161.51,159.89,159.86,133.75,133.73,132.43,132.39,130.95,130.90,122.17,122.02,114.39, 114.24,42.83,42.71,38.82; HR-ESI-MS m/z:Calcd for C13H10N3O2S2FCl{[M + H]+} 357.988 2,found 357.988 1。

      N-5-(6-氯-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-2-氯-乙酰胺(5h):收率85%,m.p.195℃~196℃;1H NMR δ:12.89(s,1H,NH),7.92(d,J=2.4 Hz,1H,ArH),7.56(dd,J=8.4 Hz,2.4 Hz,1H,ArH),7.44(d,J=8.4 Hz,1H,ArH),5.45(t,J=4.8 Hz,1H,2-H),4.41(s,2H,CH2Cl),3.48(dd,J=17.4 Hz,4.8 Hz,1H,3-H),3.41(dd,J=17.4 Hz,4.8 Hz,1H,3-H);13C NMR δ:191.10,166.01,164.59,159.90,137.06,133.99,132.05,131.13,130.62,127.63,42.71,41.93,38.72; HR-ESI-MS m/z:Calcd for C13H10N3O2S2FCl { M + H]+} 373.958 6,found 373.959 0。

      N-5-(6,8-二甲基-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-2-氯-乙酰胺(5i):收率80%,m.p.190℃~192℃;1H NMR δ:12.88(s,1H,NH),7.69(s,1H,ArH),7.27(s,1H,ArH),5.40(t,J=4.8 Hz,1H,2-H),4.40(s,2H,CH2Cl),3.45(dd,J=17.1 Hz,4.8 Hz,1H,3-H),3.34(dd,J=17.0 Hz,4.8 Hz,1H,3-H),2.26(s,3H,ArCH3),2.23(s,3H,ArCH3);13C NMR δ:192.40,165.98,165.18,159.73,136.36,135.78,134.79,134.29,130.92,126.55,42.96,42.71,38.15,20.70,19.85; HR-ESI-MS m/z:Calcd for C15H15N3O2S2Cl{[M + H]+} 368.028 9,found 368.029 1。

      N-5-(6-甲基-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-2-氯-乙酰胺(5j):收率80%,m.p.290℃~293℃;1H NMR δ:12.87(s,1H,NH),7.34~7.27(m,3H,ArH),5.37(t,J=4.8 Hz,1H,2-H),4.40(s,2H,CH2Cl),3.45(dd,J=16.8 Hz,4.8 Hz,1H,3-H),3.36(dd,J=16.8 Hz,4.8 Hz,1H,3-H),2.29(s,3H,ArCH3);13C NMR δ:192.12,169.89,162.25,159.56,135.93,135.34,134.69,130.56,128.70,128.46,43.33,42.71,38.89,21.15; HR-ESI-MS m/z:Calcd for C14H13N3O2S2Cl{[M + H]+} 354.013 2,found 354.013 4。

      N-5-(6-氟-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-3-氯-丙酰胺(5k):收率85%,m.p.176℃~178℃;1H NMR δ:12.65(s,1H,NH),7.71(dd,J=9.4 Hz,2.8 Hz,1H,ArH),7.45~7.36(m,2H,ArH),5.41(t,J=4.8 Hz,1H,2-H),3.87(t,J=6.0 Hz,2H,CH2Cl),3.48(dd,J=17.4 Hz,4.8 Hz,1H,3-H),3.39(dd,J=17.4 Hz,4.8 Hz,1H,3-H),2.96(td,J=6.0 Hz,1.5 Hz,2H,NCOCH2);13C NMR δ:191.34,169.14,164.31,161.49,159.87,159.74,133.82,133.78,132.42,132.38,130.94,130.90,122.18,122.03,114.40,114.25,42.85,38.80,38.41,36.23; HR-ESI-MS m/z:Calcd for C14H12N3O2S2FCl{[M +H]+}372.003 8,found 372.004 5。

      N-5-(6-氯-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-3-氯-丙酰胺(5l):收率80%,m.p.145℃~148℃;1H NMR δ:12.75(s,1H,NH),7.92(d,J=2.4 Hz,1H,ArH),7.56(dd,J=8.4 Hz,2.4 Hz,1H,ArH),7.44(d,J=8.4 Hz,1H,ArH),5.45(t,J=4.8 Hz,1H,2-H),3.77(t,J=6.0 Hz,2H,CH2Cl),3.48(dd,J=16.8 Hz,4.8 Hz,1H,3-H),3.41(dd,J=16.8 Hz,4.8 Hz,1H,3-H),2.90(td,J=6.0 Hz,1.5 Hz,2H,NCOCH2);13C NMR δ:191.13,164.42,163.52,160.13,133.99,132.06,131.09,130.62,129.34,127.64,42.78,42.03,38.70,36.92; HR-ESI-MS m/z:Calcd for C14H12N3O2S2Cl2{[M +H]+}387.977 1,found 387.977 1。

      N-5-(6-氟-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-4-氯-丁酰胺(5m):收率80%,m.p.207℃~209℃;1H NMR δ:12.54(s,1H,NH),7.70(dd,J=9.4 Hz,2.9 Hz,1H,ArH),7.46~7.39(m,2H,ArH),5.40(t,J=4.8 Hz,1H,2-H),3.66(td,J=7.2 Hz,4.3 Hz,2H,NCOCH2),3.48(dd,J=17.4 Hz,4.8 Hz,1H,3-H),3.38(dd,J=17.4 Hz,4.8 Hz,1H,3-H),2.60(t,J=7.2 Hz,2H,CH2Cl),2.05~2.00(m,2H,NCOCCH2);13C NMR δ:191.35,174.10,171.21,164.04,161.48,159.89,133.83,133.81,132.42,132.38,130.94,130.89,122.17,122.01,114.39,114.24,45.08,42.87,38.80,32.52,27.74; HR-ESI-MS m/z:Calcd for C15H14N3O2S2FCl{[M +H]+}386.019 5,found 386.020 4。

      N-5-(6-氯-硫色滿-4-酮-2-基)-[1,3,4]噻二唑-2-基-4-氯-丁酰胺(5n):收率85%,m.p.218℃~220℃;1H NMR δ:12.55(s,1H,NH),7.92(d,J=2.5 Hz,1H,ArH),7.56(dd,J=8.5 Hz,2.5 Hz,1H,ArH),7.43(d,J=8.4 Hz,1H,ArH),5.42(t,J=4.8 Hz,1H,2-H),3.66(td,J=7.2 Hz,4.5 Hz,2H,3-H),3.47(dd,J=16.8 Hz,4.8 Hz,1H,3-H),3.40(dd,J=16.8 Hz,4.8 Hz,1H,3-H),2.61(t,J=7.2 Hz,2H,CH2Cl),2.05~2.00(m,2H,NCOCCH2);13C NMR δ:191.13,171.22,163.92,159.93,137.17,133.98,132.08,131.08,130.62,127.63,45.08,42.81,38.72,32.52,27.75; HRESI-MS m/z:Calcd for C15H14N3O2S2Cl2{[M + H]+} 401.989 9,found 401.989 0。

      1.3體外抗真菌活性測(cè)試

      采用微量稀釋法測(cè)定了5a~5n對(duì)5種真菌的抗菌活性。將5用二甲基亞砜溶解,再用無菌蒸餾水稀釋至(128,64,32,16,8,4,2)μg· mL-1。加入已滅菌的1%葡萄糖蛋白胨瓊脂培養(yǎng)基中,接種供試菌(每種菌同時(shí)作一空白對(duì)照),置恒溫烘箱中培養(yǎng)5 d~7 d測(cè)定化合物對(duì)真菌的抑制活性,計(jì)算最小抑菌濃度(MIC值)。以兩性霉素B和氟康唑?yàn)殛栃詫?duì)照。

      2 結(jié)果和討論

      2.1表征

      以5b為例。1H NMR分析表明:δ 12.49處吸收峰歸屬酰胺(NH)質(zhì)子,在δ 7.92~7.44的吸收峰為苯環(huán)質(zhì)子,δ 5.42是硫色滿酮母環(huán)上2-位質(zhì)子吸收峰。在硫色滿酮母環(huán)中,與羰基相連的亞甲基上的兩個(gè)氫互相偶合,并受到鄰碳上一個(gè)氫的偶合作用,裂分為dd峰,δ在3.47~3.40,乙酰胺甲基的δ出現(xiàn)在2.15。

      13C NMR分析表明:兩個(gè)羰基碳的δ分別為195.90和173.97,噻二唑中兩個(gè)碳的δ分別為168.59和164.76,苯環(huán)碳的δ分別為141.94,138.78,136.83,135.82,135.40和132.38。硫色滿酮3-位碳的δ為47.54,硫色滿酮2-位碳的δ 為43.44,乙酰胺上甲基碳的δ為27.54。

      2.2抗真菌活性

      5的抗真菌活性見表1。由表1可見,5a~5n 對(duì)C.n,C.a和C.k均表現(xiàn)出較弱的抑制作用,

      表1 5a~5n的抗真菌活性*Table 1 Antifungal activities of 5a~5n

      圖1 5a~5n的抗真菌活性Figure 1 Antifungal activities of 5a~5n

      但是對(duì)E.f和M.r有良好的抑制作用。為此,對(duì)其進(jìn)行進(jìn)一步的研究,結(jié)果見圖1。由圖1可見,5a,5c,5d,5g和5m對(duì)E.f和M.r有較好的抗真菌活性,其中5c和5m對(duì)E.f和M.r的抑制活性優(yōu)于陽性對(duì)照藥物氟康唑(F,對(duì)E.f和M.r的MIC分別為32 μg·mL-1和64 μg·mL-1),5c 和5m對(duì)E.f和M.r的MIC均可達(dá)16 μg· mL-1; 5a對(duì)M.r的MIC達(dá)16 μg·mL-1; 5d和5g對(duì)E.f的MIC達(dá)16 μg·mL-1。

      3 結(jié)論

      以取代苯硫酚為原料,經(jīng)3步反應(yīng),設(shè)計(jì)并合成了14個(gè)未見文獻(xiàn)報(bào)道的含1,3,4-噻二唑的硫色滿酮衍生物(5a~5n)。生物活性測(cè)定結(jié)果顯示:5a~5n對(duì)C.n,C.a和C.k均表現(xiàn)出較弱的抑制作用,對(duì)E.f和M.r有良好的抑制作用。5a,5c,5d,5g和5m有較好的抗真菌活性,其中5a 對(duì)M.r的MIC為16 μg·mL-1; 5d和5g對(duì)E.f 的MIC為16 μg·mL-1; 5c和5m對(duì)E.f和M.r 的MIC均在16 μg·mL-1,優(yōu)于陽性對(duì)照藥物氟康唑,可作為先導(dǎo)結(jié)構(gòu)進(jìn)行優(yōu)化研究。

      參考文獻(xiàn)

      [1]Matysiak J,Malinski Z.2-(2,4-Dihydroxyphenyl)-1,3,4-thiadiazole analogues:Antifungal activity in vitro against Candida species[J].Russ J Bioorg Chem,2007,33:594-601.

      [2]Amir M,Kumar H,Javed S A.Non-carboxylic analogues of naproxen:Design,synthesis,and pharmacological evaluation of some 1,3,4-oxadiazole/thiadiazole and 1,2,4-triazole derivatives[J].Arch Pharm Chem Life Sci,2007,340:577-585.

      [3]Rzeski W,Matysiak J.Anticancer,neuroprotective activities and computational studies of 2-amino-1,3,4-thiadiazole based compound[J].Bioorg Med Chem,2007,15:3201-3207.

      [4]Hamad N S,Al-Haidery N H,Al-Masoudi I.Amino acid derivatives,part 4:Synthesis and anti-HIV activity of new naphthalene derivatives[J].Arch Pharm Chem Life Sci,2010,343:397-403.

      [5]Rebolledo C L,Sotelo-Hitschfeld P,Brauchi S,et al.Design and synthesis of conformationally restricted capsaicin analogues based in the 1,3,4-thiadiazole heterocycle reveal a novel family of transient receptor potential vanilloid 1(TRPV1)antagonists[J].Eur J Med Chem,2013,66:93-203.

      [6]Shen L H,Li H Y,Shang H X,et al.Synthesis and cytotoxic evaluation of new colchicine derivatives bearing 1,3,4-thiadiazole moieties[J].Chin Chem Lett,2013,24:299-302.

      [7]Veitch N C,Grayer R J.Flavonoids and their glycosides including anthocyanins[J].Nat Prod Rep,2008,25:555-611.

      [8]Li H Y,Hu C.Survey on biological activities of 4-chromones and 4-chromanones[J].Chin Pharm J,2005,40:241-244.

      [9]Zheng W,Sun G,Sun B J,et al.Study on the synthesis and anti-inflammatory activity of chromanones derivatives [J].Fine Chem Intermediates,2009,39:30-33.

      [10]Bulzomi P,Bolli A,Galluzzo P,et al.Naringenin and 17β-estradiol coadministration prevents hormoneinduced human cancer cell growth[J].IUBMB Life,2010,62:51-60.

      [11]Siddaiah V,Maheswara M,Venkata Rao C,et al.Synthesis,structural revision,and antioxidant activities of antimutagenic homoisoflavonoids from Hoffmanosseggia intricata[J].Bioorg Med Chem Lett,2007,17:1288-1290.

      [12]Mahapatra T,Jana N,Nanda S.Chemoenzymatic synthesis and resolution of compounds containing a quaternary stereocenters adjacent to a carbonyl group[J].Tetrahedron:Asymmetr,2008,19:1224-1232.

      [13]Meng L G,Liu H F,Wei J L,et al.One-pot reaction of ortho-acylphenols and terminal alkynoates for synthesis of 2-alkyl-substituted chromanones[J].Tetrahedron Lett,2010,51:1748-1750.

      ·研究論文·

      ·研究論文·

      Synthesis and Antifungal Activities of Novel Thiochromanone Derivatives Containing 1,3,4-Thiadiazole

      LIANG Guo-chao1a,1b,ZHOU Guan1a,1b,
      ZHONG Yi-fan1a,1b,HAN Xiao-yan1a,1b,SONG Ya-li1a,1b
      (a.Key Laboratory for Pharmaceutical Quality Control of Hebei Province,College of Pharmaceutical; b.Key Laboratory of Medicinal Chemistry and Molecular Diagnosis,Ministry of Education,1.Hebei University,Baoding 071002,China)

      Abstract:4-Thiochromane-2-carboxylic acid derivatives(2a~2d)were prepared by Michael addition reaction of substituted thiophenol with maleic anhydride.2-(5-amino-1,3,4-thiadiazol-2-yl)thiochroman-4-one derivatives(3a~3d)were prepared by acylation reaction of 2a~2d with thiosemicarbazide,respectively.Fourteen novel thiochromanone derivatives(5a~5n)containing 1,3,4-thiadiazole were synthesized by reaction of 3a~3d with acyl chloride.The structures were characterized by1H NMR,13C NMR and HR-ESI-MS.The antifungal activities of 5a~5n were investigated by micro dilution method.The results showed that some derivatives exhibited better antifungal activities on Epidermophyton floccosum and Mucor racemosus than Fluconazole.

      Keywords:thiochromanone; 1,3,4-thiadazole; synthesis; antifungal activity

      作者簡(jiǎn)介:梁國超(1989-),男,漢族,河北遷西縣人,碩士研究生,主要從事藥物化學(xué)的研究。E-mail:endyliang@126.com

      基金項(xiàng)目:“重大新藥創(chuàng)制”國家科技重大專項(xiàng)(2012ZX09103-101-057);河北省藥物質(zhì)量分析控制重點(diǎn)實(shí)驗(yàn)室開放基金資助

      收稿日期:2015-09-15

      DOI:10.15952/j.cnki.cjsc.1005-1511.2015.12.1100 *

      文獻(xiàn)標(biāo)識(shí)碼:A

      中圖分類號(hào):O626; O621.3

      猜你喜歡
      噻二唑乙酰胺酰胺
      1,3,4-噻二唑取代的氮唑類化合物的合成及體外抗真菌活性
      雙酰胺類殺蟲劑Broflanilide
      三氟咪啶酰胺的合成工藝研究
      1,3,4-噻二唑類衍生物在農(nóng)藥活性方面的研究進(jìn)展
      百里香精油對(duì)硫代乙酰胺誘導(dǎo)的小鼠急性肝損傷的保護(hù)作用
      1,3,4-噻二唑衍生物的合成與應(yīng)用
      復(fù)合溶劑萃取N,N-二甲基乙酰胺
      水體中二氯乙酰胺以及磺胺甲惡唑?qū)Π唏R魚的毒性研究
      國外二硝酰胺銨的發(fā)展現(xiàn)狀
      兩種含1,3,4-噻二唑α-氨基膦酸酯與蛋白質(zhì)弱相互作用的ESI-MS研究
      隆子县| 恩平市| 大连市| 四会市| 南充市| 开远市| 光泽县| 溧阳市| 祁连县| 上饶市| 柳河县| 山阴县| 建宁县| 铜川市| 弋阳县| 五华县| 宜宾市| 垣曲县| 美姑县| 蓬莱市| 临湘市| 温泉县| 静海县| 崇明县| 积石山| 双鸭山市| 阿巴嘎旗| 靖西县| 原阳县| 德兴市| 绥芬河市| 积石山| 门头沟区| 宁强县| 花莲县| 肥乡县| 延长县| 黄陵县| 闻喜县| 镇原县| 凤山市|